Gene and cell therapy group Oxford Biomedica on Wednesday said it had signed a new license and supply agreement on its LentiVector platform with US-based Cabaletta Bio.
The deal gives Cabaletta a non-exclusive licence for LentiVector to be used on Chimeric autoantibody receptor T programme, DSG3-CAART, for autoimmune disease.
No financial details were revealed, but Oxford Biomendica said the arrangements of the LSA were “in line with comparable deals the group has previously secured”.
